| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 关于提前赎回雪榕转债的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"雪榕转债"赎回价格：100.93 元/张（含当期应计利息，当期年利率为 3.00%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有限责任公 司深圳分公司（以下简称"中国结算"）核准的价格为准。 2、赎回条件满足日：2025 年 9 月 3 日 3、停止交易日：2025 年 10 月 10 日 4、赎回登记日：2025 年 10 月 14 日 5、赎回日：2025 年 10 月 15 日 6、停止转股日：2025 年 10 月 15 日 7、赎回资金到账日（到达中国结算账户）：2025 年 10 月 20 日 上海雪榕生物科技股份有限公司 8、投资者赎回款到账日：2025 年 10 月 22 日 9、赎回类别：全部赎回 10、最后一个交易日（2025 年 10 月 9 日）可转 ...

国浩律师（上海）事务所 上海雪榕生物科技股份有限公司 可转换公司债券提前赎回的 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二〇二五年九月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于上海雪榕生物科技股份有限公司 可转换公司债券提前赎回的 关于 法律意见书 致：上海雪榕生物科技股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受上海雪榕生物科技股份 有限公司（以下简称"雪榕生物"或"公司"）委托，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《可转换公司债券管理办法》（以下简称"《管理办法》"）、《深圳证券交易所上市 公司自律监管指引第 15 ...

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-083 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 第五届董事会第三十二次会议决议公告 本公司及出席本次董事会的董事会全体成员保证信息披露内容的真实、准确 和完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长杨勇萍先生召集，会议通知于 2025 年 8 月 27 日以 电子邮件等通讯方式发出。 2、本次董事会于 2025 年 9 月 3 日在上海雪榕生物科技股份有限公司（以下 简称"公司"）会议室召开，采取现场和通讯相结合的方式进行表决。 3、本次会议应出席董事 7 人，实际出席董事 7 人。 4、本次董事会由董事长杨勇萍先生主持，公司监事、高级管理人员列席了 本次董事会。 5、本次董事会会议的召集、召开和表决程序符合《公司法》等法律、法规 及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于提前赎回"雪榕转债"的议案》 经审议，董事会认为：自2025年8月14日至2025年9月 ...

Market Overview - The planting industry sector experienced a decline of 1.92% on September 3, with Kangnong Seed Industry leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Individual Stock Performance - Kangnong Seed Industry (837403) closed at 26.42, down 10.74% with a trading volume of 93,300 shares and a transaction value of 271 million yuan [1] - Qiule Seed Industry (831087) closed at 17.00, down 6.54% with a trading volume of 95,500 shares and a transaction value of 169 million yuan [1] - Shennong Seed Industry (300189) closed at 4.81, down 4.94% with a trading volume of 1.614 million shares and a transaction value of 800 million yuan [1] - Other notable declines include: - Quanyin High-Tech (300087) down 3.75% - Xuecheng Biological (300511) down 3.51% [1] Capital Flow Analysis - The planting industry sector saw a net outflow of 378 million yuan from institutional investors, while retail investors contributed a net inflow of 208 million yuan [1] - The following stocks had significant capital flows: - Honghui Fruits and Vegetables (603336) saw a net inflow of 9.33 million yuan from institutional investors [2] - New Agricultural Development (600359) had a net inflow of 289.78 million yuan from institutional investors [2] - Wanxiang Denong (600371) experienced a net outflow of 297.60 million yuan from institutional investors but a net inflow of 285.48 million yuan from retail investors [2]

Market Overview - The planting industry sector declined by 0.69% on September 2, with Nopson leading the decline [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] Individual Stock Performance - Kangnong Agricultural (837403) saw a significant increase of 6.59%, closing at 29.60 with a trading volume of 86,500 shares and a turnover of 251 million yuan [1] - Nopson (002215) experienced a decline of 2.93%, closing at 11.93 with a trading volume of 394,200 shares and a turnover of 471 million yuan [2] - Other notable performers include Shennong Agricultural (681000E) with a 1.20% increase, and Huagu Biological (300970) remaining flat at 9.33 [1][2] Capital Flow Analysis - The planting industry sector experienced a net outflow of 108 million yuan from institutional investors, while retail investors saw a net inflow of 112 million yuan [2] - The capital flow for individual stocks indicates that Shennong Agricultural had a significant net outflow of 68.06 million yuan from institutional investors [3] - In contrast, Huagu Biological had a net inflow of 22.29 million yuan from retail investors, indicating a mixed sentiment among different investor types [3]

Core Viewpoint - Xuerong Biological (300511) reported a decline in total revenue and a negative net profit for the first half of 2025, but showed improvements in profitability metrics such as gross margin and net margin [1] Financial Performance - Total revenue for the first half of 2025 was 791 million yuan, a decrease of 26.17% year-on-year [1] - Net profit attributable to shareholders was -103 million yuan, an increase of 28.58% year-on-year [1] - In Q2 2025, total revenue was 350 million yuan, down 25.04% year-on-year [1] - Q2 2025 net profit attributable to shareholders was -110 million yuan, an increase of 26.23% year-on-year [1] Profitability Metrics - Gross margin increased by 207.28% year-on-year to 1.24% [1] - Net margin improved by 3.91% year-on-year to -12.3% [1] - Total selling, administrative, and financial expenses amounted to 113 million yuan, accounting for 14.3% of revenue, an increase of 9.08% year-on-year [1] Cash Flow and Debt - Cash flow per share was 0.23 yuan, an increase of 67.62% year-on-year [1] - The company had 764.12 million yuan in cash, a decrease of 80.35% year-on-year [1] - Interest-bearing liabilities decreased by 42.44% year-on-year to 1.533 billion yuan [1] Historical Performance - The company's historical median ROIC since listing is 8.22%, with the worst year being 2024 at -15.67% [3] - The company has reported losses in 4 out of 8 annual reports since its listing [3] - The cash flow situation is concerning, with cash to current liabilities ratio at only 6.26% [3] - The interest-bearing debt ratio has reached 41.57% [3]

Group 1 - The core point of the article is that Xuerong Biotechnology (SZ 300511) held its 31st meeting of the 5th Board of Directors on August 26, 2025, to review the semi-annual report and its summary for 2025 [1] - For the year 2024, Xuerong Biotechnology's revenue composition shows that the edible mushroom industry accounts for 98.62%, while other businesses contribute 1.38% [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related listed companies [1]

Core Viewpoint - Xuerong Bio's stock price closed at 6.73 yuan on August 26, down 1.03% from the previous trading day, with a trading volume of 150,942 hands and a transaction amount of 102 million yuan [1] Company Overview - The company specializes in the research, production, and sales of edible mushrooms, with main products including enoki mushrooms and king oyster mushrooms [1] - Xuerong Bio operates within the agriculture, animal husbandry, and fishery industry, and is also involved in agricultural planting and plant-based meat sectors [1] Financial Performance - In the first half of 2025, the company reported operating revenue of 791 million yuan, a year-on-year decrease of 26.17% [1] - The net profit attributable to the parent company was a loss of 103 million yuan [1] Capital Flow - On August 26, the net outflow of main funds was 7.4632 million yuan, with a cumulative net outflow of 21.9462 million yuan over the past five days [1]

Group 1 - The company announced that its wholly-owned subsidiary, Chengdu Xuerong, plans to apply for a comprehensive credit line of up to 5 million yuan from Chengdu Rural Commercial Bank [1] - Chengdu Xuerong will provide a credit guarantee through Jinxin Financing Guarantee Co., Ltd. as required by the bank [1] - The total approved external guarantee amount for the company and its subsidiaries, including this guarantee, is 323,120.96 thousand yuan, with an actual guarantee balance of 111,182.51 thousand yuan, representing 28.84% of the company's audited total assets and 135.04% of its net assets for the year 2024 [1]

Group 1 - The core viewpoint of the article is that Xuerong Bio reported a significant decline in revenue and incurred a net loss in the first half of 2025 [1] Group 2 - The company achieved an operating income of 791 million yuan, which represents a year-on-year decrease of 26.17% [1] - The net profit attributable to the parent company was a loss of 103 million yuan [1]